Skip to main content

ForgingBridges | NULIBRY Access and Support is committed to providing affordability options to help your child get NULIBRY as soon as possible

ForgingBridges | NULIBRY offers financial assistance options to help you manage the cost of NULIBRY.

Benefits Verification

ForgingBridges | NULIBRY will automatically do an insurance benefits verification for all NULIBRY families.

  • Determine your insurance status
  • Support any insurance denials or delays
  • Provide a sample appeals letter (if you need it)
  • Communicate any copay responsibility you may have

ForgingBridges | NULIBRY Copay Assistance Program

Speak with your healthcare provider or care team about the Copay Assistance Program and other access and affordability programs for which you may be eligible.

You must be commercially insured and have a copay of more than $0. The maximum benefit provided to any one patient via the ForgingBridges | NULIBRY Copay Assistance Program is $100,000 per year.

forging bridges access support program logo

ForgingBridges | NULIBRY
Access and Support

For questions or additional info, give us a call. Our support team is ready to help.

Call 1-888-55BRIDGE

Monday-Friday, 8 am-8 pm ET

The support you need starts here.

Program Enrollment Form >



NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.



Potential for Photosensitivity

NULIBRY can make the patient oversensitive to sunlight. NULIBRY-treated patients or their caregivers are advised to avoid or minimize patient exposure to sunlight and artificial UV light and adopt precautionary measures when exposed to the sun, including wearing protective clothing and sunglasses, and use broad-spectrum sunscreen with high SPF in patients 6 months of age and older. If photosensitivity occurs, caregivers/patients are advised to seek medical attention immediately and consider a dermatological evaluation.


The most common adverse reactions in NULIBRY-treated patients were infusion catheter–related complications (89%), pyrexia (fever) (78%), viral infection (56%), pneumonia (44%), otitis media (ear infection) (44%), vomiting (44%), and cough/sneezing (44%). Adverse reactions for rcPMP-treated patients were similar to the NULIBRY-treated patients.


Please read the FDA-approved NULIBRY Prescribing Information and Instructions for Use and follow the instructions on how to prepare and administer NULIBRY.

NULIBRY has a potential for photosensitivity; see Warnings and Precautions. Seek medical attention immediately if the patient develops a rash or if they notice symptoms of photosensitivity reactions (redness, burning sensation of the skin, blisters).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.